

Table 2-a. Crude hazard ratios for death associated with HER2 positivity with trastuzumab therapy and other prognostic factors related to BC and HF

	Overall			Late phase		
	HR	(95% CI)	P value	HR	(95% CI)	P value
Trastuzumab on HER2 (+) (yes / no)	0.40	(0.20 – 0.79)	0.009	0.29	(0.13 – 0.67)	0.004
Age (per +1 year)	1.00	(0.97 – 1.04)	0.884	1.02	(0.97 – 1.07)	0.516
BMI (per +1.0 kg/m ²)	0.90	(0.81 – 0.99)	0.029	0.87	(0.75 – 1.00)	0.054
Serum total protein (per +1 mg/dL)	0.67	(0.42 – 1.07)	0.093	0.69	(0.36 – 1.32)	0.261
Metastasis (present = stage 4 / absent =stage 3 or less)	7.19	(3.00 – 17.21)	0.000	7.38	(2.90 – 18.77)	0.000
Doxorubicin equivalent cumulative dose (per +100 mg/m ²)	1.11	(0.98 – 1.24)	0.098	1.09	(0.94 – 1.25)	0.255
Estrogen receptor (positive / negative)	1.35	(0.73 – 2.52)	0.340	1.26	(0.57 – 2.75)	0.568
Progesterone receptor (positive / negative)	1.34	(0.72 – 2.49)	0.353	1.09	(0.50 – 2.37)	0.835
Heart disease (present / absent)	0.64	(0.23 – 1.80)	0.399	0.77	(0.26 – 2.22)	0.623
Low LVEF (less than 35%, yes / no)	1.22	(0.56 – 2.64)	0.619	0.89	(0.33 – 2.36)	0.808
NT-proBNP (per +100 pg/mL)	1.01	(1.00 – 1.03)	0.038	1.01	(1.00 – 1.03)	0.041
History of HF hospitalization (yes / no)	0.82	(0.43 – 1.57)	0.546	0.91	(0.40 – 2.04)	0.811
ACEIs or ARBs	0.77	(0.41 – 1.44)	0.407	0.80	(0.37 – 1.73)	0.568
Beta blockers	0.68	(0.34 – 1.33)	0.254	0.63	(0.28 – 1.42)	0.266
MRAs	0.69	(0.36 – 1.31)	0.254	0.63	(0.28 – 1.42)	0.262

Table 2-b. Adjusted hazard ratios for death associated with HER2 positivity with trastuzumab therapy and possible confounding factors

	Overall			Late phase		
	HR	(95% CI)	<i>P</i>	HR	(95% CI)	<i>P</i>
Trastuzumab on HER2 (+) (yes / no)	0.44	(0.21 – 0.90)	0.024	0.24	(0.10 – 0.56)	0.001
BMI (per +1.0 kg/m ²)	0.90	(0.82 – 0.99)	0.027	0.93	(0.80 – 1.07)	0.300
Metastasis (present = stage 4 / absent =stage 3 or less)	5.85	(2.43 – 14.11)	0.000	7.18	(2.75 – 18.75)	0.000